Recent studies show that the coronavirus pathogen (SARS-CoV-2) is responsible for the cytokine storm that makes COVID-19 disease deadly. Mesenchymal stem cells can be used as an advanced therapy drug for the treatment of pneumonia caused by COVID-19 due to the immunomodulatory and regenerative properties of these cells.
As Song et. Al. demonstrated in the journal Stem Cells. 2021; 1–16 (Mesenchymal stem cell immunomodulation: In pursuit of controlling COVID‐19 related cytokine storm (nih.gov) the immunomodulatory effect of mesenchymal stem cells counteracts the cytokine storm by promoting an anti-inflammatory environment and promoting tissue repair lung cells.
In fact, the mesenchymal cells, infused into the patient suffering from the disease, release anti-inflammatory molecules that modulate the activity of T cells, neutrophils and macrophages.
From this scientific evidence, treatments that use adipocyte mesenchymal stem cells for allogeneic transplants on selected patients affected by COVID-19 are still underway and are in the clinical trial phase. This innovative therapy is able to avoid patients, going into intensive care by slowing down and reducing the course of pneumonia.
Once again, advanced therapies prove to be an intelligent weapon that cannot be used by conventional drugs for the treatment of pathologies that are still little known.